Interobserver and Intraobserver Variability of Standardized Uptake Value Measurements in Non–small-cell Lung Cancer

Objectives To assess interobserver and intraobserver variabilities in measuring the maximal standardized uptake value (SUV) of non–small-cell lung cancer. Methods Positron emission tomography-computed tomography examinations of 20 consecutive patients referred for initial evaluation of newly diagnosed non–small-cell lung cancer were retrospectively reviewed by 5 experienced positron emission tomography-computed tomography readers, who independently measured the maximal SUV/body weight of the primary tumors. Interobserver and intraobserver variabilities were assessed by using 4 statistical methods: correlation, regression analysis, Bland-Altman analysis, and analysis of variance. The SUV measurements derived in the study were compared with the SUV measurements documented in the original reports using correlation and regression analysis. The percentages of tumors whose retrospective SUV measurements were more than 20% different and more than 25% different from those in the original report were assessed. Results Both interobserver and intraobserver SUV measurements were highly reproducible. Pearson correlation coefficients were greater than 0.95 and 0.94, respectively. Good interobserver and intraobserver agreement was shown with regression analysis (F test P value >0.05), the Bland-Altman analysis, and analysis of variance (F test P value >0.95). The mean original SUV was much less than the mean study SUV (P<0.05). The study SUV differed from the SUV of the original report by more than 20% in 50% of the tumors, and by more than 25% in 45% of the tumors. Conclusions There was excellent interobserver and intraobserver agreement in SUVs measured in the study environment but poor agreement between study SUVs and those documented in original reports, which can affect treatment decisions substantially.

[1]  H. Schäfers,et al.  Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. , 2004, The Journal of thoracic and cardiovascular surgery.

[2]  S. Larson,et al.  Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Pevsner,et al.  The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  Mithat Gonen,et al.  Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  Kenneth E Rosenzweig,et al.  Reduction of respiratory motion artifacts in PET imaging of lung cancer by respiratory correlated dynamic PET: methodology and comparison with respiratory gated PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  J Nuyts,et al.  18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). , 2003, European journal of cancer.

[7]  M. Schwaiger,et al.  Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Larson,et al.  Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Keigo Endo,et al.  Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. , 2002, American journal of surgery.

[10]  D. Mankoff,et al.  Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. , 2002, Academic radiology.

[11]  J. Wildberger,et al.  Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma , 2002, Bone Marrow Transplantation.

[12]  Mohamed Allaoua,et al.  Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Fischman,et al.  FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. , 2002, Lung cancer.

[14]  J. Vansteenkiste Imaging in lung cancer: positron emission tomography scan , 2002, European Respiratory Journal.

[15]  Elisabeth Kjellén,et al.  FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma , 2002, Head & neck.

[16]  D. Visvikis,et al.  Influence of OSEM and segmented attenuation correction in the calculation of standardised uptake values for [18F]FDG PET , 2001, European Journal of Nuclear Medicine.

[17]  Sung-Cheng Huang,et al.  Anatomy of SUV , 2000 .

[18]  M. O'Doherty,et al.  [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. , 2000, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[19]  A. Gregor,et al.  Randomized trial of surgery versus radiotherapy in patients with stage IIIA (N2) non small-cell lung cancer after a response to induction chemotherapy. EORTC 08941. , 2000, Clinical lung cancer.

[20]  John L. Humm,et al.  Use of PET to monitor the response of lung cancer to radiation treatment , 2000, European Journal of Nuclear Medicine.

[21]  P A Salvadori,et al.  Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. , 2000, Clinical breast cancer.

[22]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[23]  John L. Humm,et al.  Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[24]  D. Altman,et al.  Measuring agreement in method comparison studies , 1999, Statistical methods in medical research.

[25]  P. Dupont,et al.  Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  R. Coleman,et al.  The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma , 1998, Cancer.

[27]  N. Choi,et al.  Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M Schwaiger,et al.  Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. , 1996, Journal of the National Cancer Institute.

[29]  M Schwaiger,et al.  Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Keyes SUV: standard uptake or silly useless value? , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  T. Olencki,et al.  Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer. , 1995, The Annals of thoracic surgery.

[32]  J. Crowley,et al.  Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R L Wahl,et al.  Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. , 1995, Radiology.

[34]  J. Bergh,et al.  Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J M Hoffman,et al.  Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  J. Roth,et al.  A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. , 1994, Journal of the National Cancer Institute.

[37]  J. Mate,et al.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. , 1994, The New England journal of medicine.

[38]  O. Hoekstra,et al.  Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography , 1993, European Journal of Nuclear Medicine.

[39]  M. Kris,et al.  Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Kris,et al.  Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. , 1993, The Annals of thoracic surgery.

[41]  N. Choi,et al.  Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  S. Steinberg,et al.  Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. , 1992, The Annals of thoracic surgery.

[43]  P. Valk,et al.  Assessment of Treatment Response by FDG-PET , 2006 .

[44]  D. Podoloff,et al.  The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[45]  Frank Griesinger,et al.  Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning. , 2003, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[46]  N. Sadato,et al.  FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[47]  C. E. al Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma , 2002, Bone Marrow Transplantation.

[48]  Yukiko Arisaka,et al.  18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  S. Larson,et al.  An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. , 2002, The Annals of thoracic surgery.

[50]  S C Huang,et al.  Anatomy of SUV. Standardized uptake value. , 2000, Nuclear medicine and biology.

[51]  J. Menten,et al.  Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a review. The Leuven Lung Cancer Group. , 1998, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[52]  J. Clark,et al.  Combined modality therapy for stage IIIA non-small cell carcinoma of the lung. , 1993, European journal of cancer.